Figure 3.

Efficacy against SARS-CoV-2 infection and viral transmission of NARUVAX-C19 vaccine in Syrian hamsters. All animals were intranasally challenged with SARS-CoV-2 Delta variant. Shown are 1) changes in body weight (a); 2) viral load in nasal turbinates and lungs (expressed as log₁₀ TCID₅₀/mL; (b) on day 3 after the challenge; 3) lung pathology on day 3 after challenge (c). The protective effect of vaccine due to the viral transmission was assessed by the weight dynamics of sentinel animals (a), viral load in respiratory organs of sentinel animals (added to the cages with challenged hamsters on day 1; b), lung pathology (c, d). Photographs were taken at x40 magnification. Scale bars are 500 µm. Differences between groups were assessed by Tukey’s, multiple comparison test. P < 0.05 was considered significant. *P < 0.05, **P < 0.01 and ***P < 0.001 and ****P < 0.0001.